Some studies have shown that blocking JAM-A on multiple myeloma cells can restore angiogenic homeostasis and inhibit tumors, that JAM-A mAb has high specificity and target binding affinity (Solimando et al., 2021), and is expected to develop into an ADC (Antibody Drug Conjugate) for multiple myeloma. This evidence concerns the gene F11R and plasma cell myeloma.